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Smooth muscle cellsThe sarco(endo)plasmic reticulum Ca2+ATPases (SERCA) system, a key regulator of calcium cycling and
signaling, is composed of several isoforms. We aimed to characterize the expression of SERCA isoforms in
mouse cardiovascular tissues and their modulation in cardiovascular pathologies (heart failure and/or
atherosclerosis).
Five isoforms (SERCA2a, 2b, 3a, 3b and 3c) were detected in themouse heart and thoracic aorta. Absolute mRNA
quantiﬁcation revealed SERCA2a as the dominant isoform in the heart (~99%). Both SERCA2 isoforms co-localized
in cardiomyocytes (CM) longitudinal sarcoplasmic reticulum (SR), SERCA3b was located at the junctional SR. In
the aorta, SERCA2a accounted for ~91% of total SERCA and SERCA2b for ~5%. Among SERCA3, SERCA3b was the
most expressed (~3.3%), mainly found in vascular smooth muscle cells (VSMC), along with SERCA2a and 2b.
In failing CM, SERCA2a was down-regulated by 2-fold and re-localized from longitudinal to junctional SR. A
strong down-regulation of SERCA2a was also observed in atherosclerotic vessels containing mainly synthetic
VSMCs. The proportion of both SERCA2b and SERCA3b increased to 9.5% and 8.3%, respectively.
In conclusion: 1) SERCA2a is the major isoform in both cardiac and vascular myocytes; 2) the expression of
SERCA2a mRNA is ~30 fold higher in the heart compared to vascular tissues; and 3) nearly half the amount of
SERCA2a mRNA is measured in both failing cardiomyocytes and synthetic VSMCs compared to healthy tissues,
with a relocation of SERCA2a in failing cardiomyocytes. Thus, SERCA2a is the principal regulator of excitation–
contraction coupling in both CMs and contractile VSMCs.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Ca2+ homeostasis plays a pivotal role in cardiovascular contractile
function. Among various Ca2+ transporters, the calcium pumps sarco/
endoplasmic reticulum Ca2+ATPase (SERCA) is the only active Ca2+
transporter in the sarcoplasmic reticulum (SR). In muscular cells,icetre, France. Tel.: +33 1 49 59SERCA controls the SR Ca2+ store that can be mobilized during muscle
contraction and it decreases cytosolic Ca2+ concentration to allow
muscle relaxation. However, Ca2+ signaling is complex and several
SERCA proteins have been described in human cardiomyocytes [1].
Regulation of their function is a key mechanism controlling not only
contractile function, but also protein expression and cellular differenti-
ation through excitation/transcription coupling [2].
The growing family of SERCA is coded by 3 ATP2A1-3 genes located
on different chromosomes, encoding for SERCA1, SERCA2 and SERCA3
isoforms respectively; further diversity is generated by alternative
splicing [3]. Isoform expression is also speciﬁc to cell-type and develop-
mental stage [3].
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fetal (b)), mostly expressed in fast-twitch skeletal muscle [3].
The SERCA2 gene gives rise to four species (a–d) through alter-
native splicing of the SERCA2 gene [1]. The so-called “cardiac
isoform” SERCA2a, is expressed in cardiac muscle, slow-twitch
skeletal muscle and smooth muscle cells, while SERCA2b is a ubiq-
uitous isoform expressed in muscle and non-muscle cells [3].
SERCA2a and SERCA2b are produced by alternative splicing of the
SERCA gene and differ only by the replacement of the last 4
amino acids of SERCA2a by an additional 49 amino acids in
SERCA2b, possibly coding for an additional trans-membrane loop
in the SR [4].
SERCA3 has various 3′-end spliced variants encoding the common
SERCA3a isoform [5], in addition to species-speciﬁc isoforms, including
5 human (SERCA3b-f) [5–7], 2 mouse (SERCA3b-c) [8] and 1 rat
(SERCA3b/c) proteins [9]. SERCA3 isoforms are mostly expressed in
non-muscle cells, especially in endothelial and hematopoietic cells,
with minor expression in muscle cells [3].
At least 14 different SERCA mRNA variants have been identiﬁed
with their corresponding proteins. Some of these isoforms are speciﬁc
to humans; to date, SERCA2c, SERCA2d, SERCA3d, SERCA3e and
SERCA3f [1].
As all the members of the SERCA family share the same efﬁciency
(transport of two Ca2+ ions per ATP), SERCA isoforms functionally
differ only by their afﬁnity for Ca2+ (2b N 2a = 1 N 2c N 3) and
their Ca2+ transport turn-over rates, SERCA2b having the lowest
transport capacity among all SERCA isoforms [3,10–12]. In-vitro
functional characterization of the main muscular SERCA isoforms
clearly indicated that SERCA2a displays a lower afﬁnity for Ca2+
but has a higher turnover rate compared to SERCA2b. SERCA3 isoforms
are characterized by an even lower Ca2+ afﬁnity but a rapid turnover
rate [13].
Several SERCA isoforms have been described in the cardiovascular
system (reviewed in [14]), particularly in human cardiomyocytes [1].
At least 6 SERCA isoforms: SERCA2a, 2b, 2c and SERCA3a, 3d and 3f
have been described in human cardiomyocytes with distinct intracellu-
lar localization [1]. Of note, in the mouse and human adult heart,
SERCA2a was described as the major cardiac isoform, while SERCA2b
appeared as the minor one [1,15].
In vascular smooth muscle cells from the rat thoracic aorta,
SERCA2a and SERCA2b mRNA were shown to account respectively
for 30% and 70% of total SERCA2 mRNA [16], and expression of
other isoforms was not reported. It is well established that SERCA2a
is down-regulated during pathologic cardiac hypertrophy and heart
failure, and its down-regulation is associated with impaired calcium
cycling, as previously reviewed in detail [17]). A similar down-
regulation of SERCA2awas observed during vascular proliferative re-
modeling (reviewed in [18,19]). Restoration of SERCA2a expression
by gene transfer improves various features of heart failure in preclin-
ical models and in phase 1 and phase 2 clinical trials [20,21]. It also
prevents VSMC proliferation in animal models of restenosis after
vascular injury [18]. Altogether, present studies demonstrate that
the physiological role of SERCA2a inmuscle cells is to regulate “contractile”
calcium cycling.
The physiological roles of other isoforms detected in the heart
(SERCA2b, SERCA2c and various SERCA3 family members (3a, 3d
and 3f)) remain unclear [1,11,22]. Reduced SERCA expression and
activity are recognized as a major event in cardiomyocyte hypertro-
phy and vascular proliferative remodeling. However, the existence of
a physiological and pathophysiological interplay between various
SERCA isoforms, potentially forming a system, has not been investi-
gated. Therefore, we aimed to characterize the expression and the
cellular localization of the SERCA isoform system in normal mouse
cardiomyocytes, vascular smooth muscle and endothelial cells
(referred to respectively as CM, VSMC, EC) and in mouse models of
heart failure and atherosclerosis.2. Material and methods
2.1. Animal models
2.1.1. Model of heart failure
Eight week old C57BL/6 male mice were purchased from Janvier
(CERJ, Saint Berthevin, France). Animals were housed at 5 per cage
under controlled environmental conditions, with 12 h light:dark cycle
at 22 °C of controlled temperature, food and water ad libitum. Animal
experimentswere conducted in agreementwith our institutional guide-
lines for the use of animals in research.
Micewere anesthetized by intraperitoneal injection of pentobarbital
sodium (50 mg/kg), intubated, and mechanically ventilated with 100%
oxygen via a positive pressure respirator (Minivent type 845, Hugo
Sachs, Elektronik-Harvard Apparatus, Germany). The ventilation rate
was 170 strokes perminute, and the tidal volumewas 200 μl. Body tem-
peraturewasmaintained at 37 °C. A left thoracotomywas performed in
the fourth intercostal space to induce left ventricular infarction
(myocardial infarction, MI) by ligation of the left anterior descending
coronary with an 8-0 Prolene, or for a sham operation (Sham). The
chest was closed in layers. Myocardial ischemia was conﬁrmed by the
occurrence of regional blanching.
Echocardiographic examinationwas performed under isoﬂurane se-
dation, using the echocardiography-Doppler (General Electric Medical
systems Co, Vivid 7 Dimension/Vivid 7 PRO) with a probe emitting ul-
trasounds with 9–14 MHz frequency. Two-dimensional images and
M-mode measurements were used to quantify left ventricular dimen-
sion and function. At least three sets of measures were obtained from
three different cardiac cycles. Echocardiography was performed at
1 month and 6 months after MI. At 6 months, the animals were
sacriﬁced and the heart was removed for morphometric analysis and
tissue sampling.
2.1.2. Model of atherosclerosis
ApoE−/− mice were purchased from Charles River. Mice were
housed under a 12-hour light/12-hour dark cycle (relative humidity:
55–60%; temperature: 22 °C) and were given standard chow and
water ad libitum. At 48 weeks of age, male mice were sacriﬁced by a le-
thal dose of pentobarbital (intra-peritoneal injection) and heart tissues
with attached aortic roots and aortaswere collected. Aortaswere imme-
diately dissected, snap frozen in RNA later (Ambion) and stored at
−80 °C for subsequent RNA extraction. Heart tissues were ﬁxed in 4%
formalin for 1 h then soaked in 20% glucose overnight. Tissueswere fro-
zen and stored at−80 °C.
2.2. Ultrasound biomicroscopy of atherosclerosis lesions in the brachiocephalic
arteries
Imageswere acquired of the brachiocephalic artery every 3 weeks in
mice starting from 30 weeks of age up to 48 weeks. Prior to ultrasound
examination, all mice were anesthetized with 3% isoﬂurane gas and
maintained lightly anesthetized with an isoﬂurane dose of 1.5% during
analysis (Minerve Veterinary Equipment, France). The hair of the
anterior chest wall was removed and ultrasound transmission gel was
applied liberally before scanning. Ultrasound examinations were per-
formed using the Ultrasound Biomicroscope (VEVO 2100, Visualsonics,
Toronto)with a 40MHzprobe (MS550D). TheUltrasoundBiomicroscope
allows real time in vivo observations at high resolution (90 and 40 μM
lateral and axial resolution, respectively) using a high frequency trans-
ducer (40 MHz). Real time visualization was assessed at 60 images/s.
Images were taken in B-mode, or 2 dimensional mode. The probe was
positioned in a right parasternal and longitudinal long- and short-axis
view at the level of the ascending aorta. More speciﬁcally, the location
transducer was at the lower 1/3rd of the chest; the direction of the
transducer was posterior and leftward, 70° with the coronal plane;
the orientation of the imaging plane was parallel to the central axis of
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spectively as the plaque close to the aortic root and the plaque close
to the bifurcation of the left subclavian artery. The long axis view in
B-mode was used to the bifurcation of the left subclavian artery.
The long axis view in B-mode was used to measure the total athero-
sclerotic plaque surface (mm2); lesions visualized in the superior
and inferior portion of the brachiocephalic artery were outlined
and measured by VEVO2100 software. The image chosen from each
ultrasonographic sequence corresponds to the one representing the
largest detected atherosclerotic plaque for all mice.
2.3. RNA extraction of aortas
Tissues were thawed and homogenized in an Ultrathurax mechani-
cal homogenizer. mRNA was extracted using the standard Trizol proto-
col (Life Technologies) until phase separation. RNA precipitation was
performed using the RNeasy Midi Kit (Qiagen) according to the
manufacturer's instructions, in order to optimize RNA collection and
reduce the risk of contamination by organic solvents. RNA quality was
determined by agarose gel electrophoresis with ethidium bromide;
the 18S and 28S RNA bands were visualized under UV light.
2.4. Histological analysis
Cardiac ﬁbrosis was determined by Sirius red staining by using a
Picrosirius Red Stain Kit (Polysciences Inc.). Cryosections were ﬁxed in
Bouin's solution (1 h, 56 °C), then stained with Sirius red. Collagen
ﬁbers in the heart stained a red color and the cardiac ﬁbrotic area was
evaluated using ImageJ software. Cardiac ﬁbrosis was quantiﬁed
including the infarct scar. The size of cardiomyocytes was evaluated
on cross sections using Wheat germ agglutinin (WGA) Alexa Fluor®
488 conjugate (Invitrogen).
2.5. Real-time quantitative reverse transcription–polymerase chain
reaction (RT-PCR) assays
Relative gene expression was determined using two-step quantita-
tive real-time PCR. Total RNA was isolated with TRIzol reagent
(Invitrogen) followed by a cleanup step as described in the RNeasy
Isolation kit (Qiagen) with on-column DNase I treatment to eliminate
contaminating genomic DNA with RNase-free DNase Set (Qiagen).
After annealing oligodT (1 μM) to template RNAs (0.5 μg) at 70 °C for
5 min, primer extension was initiated by adding the RT-MMLV enzyme
plus 0.5mMdNTP, 1U RNAsin and 10mMdithiothreitol (DTT), and car-
ried out for 45 min at 37 °C. Quantitative PCR was performed using the
Light Cycler LC480 (Roche Diagnostics). The PCR mix included 5 μl of
each reverse transcriptase (diluted 1:25) and 300 nM of each primer
in 1 × Light Cycler DNA SYBR Green 1 Master Mix. The forward and re-
verse primer sequences for complementary DNA (cDNA) of mouseTable 1
The forward and reverse primer sequences for complementary DNA (cDNA) of mouse genes.
Forward
SERCA2a CTCCATCTGCTTGTCCAT
SERCA2b CTCCATCTGCTTGTCCAT
SERCA2c CTCCATCTGCTTGTCCAT
SERCA3 GGGGTGGTGCTTCAGATGTCTC
SERCA3a GGGGTGGTGCTTCAGATGTCTC
SERCA3b GGGGTGGTGCTTCAGATGTCTC
SERCA3c GGGGTGGTGCTTCAGATGTCTC
GAPDH ACA CAT TGG GGG TAG GAA C
Calsequestrine CCT TTG AGC GCA TCG AG
E-selectin AGG GCT TTA GCT TGC AT
MHC GGC TTC ATT TGT TCC TTC CA
SM22 TAT GGC AGC AGT GCA GAG
Smoothelin TCT CAA CAG CGA GAA GC T Ggenes (Table 1) were designed with Primer Express software according
to European Molecular Biology Laboratory accession numbers.
PCRs were performed using the following thermal settings: denatur-
ation and enzyme activation at 95 °C for 5 min, followed by 40 cycles of
95 °C (10 s), 60 °C (15 s), and 72 °C (15 s). Post-ampliﬁcation dissocia-
tion curves were performed to verify the presence of a single ampliﬁca-
tion product and the absence of primer dimers. Controls and water
blanks were included in each run; they were negative in all cases. Rela-
tive expression of a target gene (SERCA) was standardized by a non-
regulated reference gene (GAPDH or calsequestrin). Real-time quantita-
tive PCR data represent the amount of each target messenger RNA
(mRNA) relative to the amount of GAPDH gene mRNA or cardiac
calsequestrin gene mRNA, estimated in the logarithmic phase of the
PCR. Each speciﬁc cDNA amplicon was puriﬁed and serial dilutions of de-
termined concentration were used to determine the ﬁt coefﬁcients of the
relative standard curve. Absolute quantiﬁcation of SERCAmRNAwas per-
formed by interpolation of its PCR signal (Cq) into this standard curve
using the Livak-Schmittgen equation: Quantity = 10(Cq − b) / m, where
b is the y-intercept and m is the slope of the linear regression [23].
2.6. Protein analysis
Immunoblots were performed according to a standard protocol.
Immunolabelings were performed on acetone-ﬁxed sections according
to a standard protocol. The following SERCA primary antibodies were
used: anti-SERCA2a and anti-SERCA2b were from afﬁnity Bioreagent,
the anti-SERCA2c was directed against the corresponding human pep-
tide (YLEPVLSSEL) that is mostly preserved in the potential mice
SERCA2c terminal part (YLEQPVLSLEP) and was produced by
Eurogentec. The anti-SERCA3a (C90)was raised against the rat sequence
LSRHHVDEKKDLK that is nearly similar to the mice sequence
LSRNHMDEKKDLK, anti-SERCA3b was speciﬁcally raised against the
mice peptide TGKKGPEVNPNPGSRGES, and the anti-SERCA3c was
directed against the human C-Terminal peptide of SERCA3c;
HTGLASLKK that is also very close to the C-terminal part of the
mice SERCA3c: HTGLASWKKRT. [1,7]. The other primary antibod-
ies used were purchased from Santa Cruz Biotechnology: anti-glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) (sc-47424), anti-
calsequestrine (sc-28274) and anti-desmin (sc-271677) and anti-
PECAM (sc-1506).
2.7. Confocal immunoﬂuorescence microscopy
Immunostaining was performed using the described upper pri-
mary antibodies and secondary antibodies conjugated to Alexa-546
or Alexa-488. Slides were examined with a Leica TCS4D confocal
scanning laser microscope equipped with a 25 mW argon laser and
a 1 mW helium-neon laser, using a Plan Apochromat 63× objective
(NA 1.40, oil immersion). Green ﬂuorescence was observed with a
505–550 nmband-pass emissionﬁlter under 488 nm laser illumination.Reverse
GCGGTTACTCCAGTATTG
GGCTGCACACACTCTTTAC
CTAAGGCTCTAAGTCGAGAA
TGC GGGGACCCTCCTGTGCTGGCTGGCC
TGC CCTTTTTTTCATCCATGTGATTCC
TGC CCTTTTTTTCCGGTGTGGTATGG
TGC TTTTCCAAGAAGCCAACCCGG
A AAC TTT GGC ATT GTG GAA
GAT GTA AGG CTG GAA GTG T
CGT CAA GGC TTG GAC ATT
GGA GCG TCC ATT TCT TCT TC
CTT TCT TCA TAA ACC AGT TGG GA
A TGG TCA ACT CCT CGA CAT CA
SERCA2a 
SERCA2b 
CRT
SERCA3a 
SERCA3b 
SERCA3c 
A B 
L R 
2a 2b 3a 3b 3c
L R L R L R L R L R 
6 µm
SERCA2a SERCA2b SERCA3b 
C 
D 
Fig. 1. Endogenous expression of SERCA 2 & 3 isoform mRNA and proteins in normal mouse heart. Expression of the different SERCA isoforms was assessed either by RT-PCR (A) or by
immunodetection (B) in left (L) or right (R) ventricle. The amount of protein loads in eachwell was controlled using detection of calreticulin (CRT) as indicated inmethods. C. Localization
of the three major SERCA isoforms (green) within the cardiomyocytes (longitudinal sections from left ventricle). Confocal immunoﬂuorescence. Red—F-actin, phalloidin staining. Arrows
indicate the position of I-band. D. Schematic representation of human and mice ATP2A2 gene and comparison between human cDNA exon 23 with the hypothetical mice analog.
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ﬁlter under 543 nm laser illumination. Pinholes were set at 1.0
airy units. Stacks of images were collected every 0.4 μm along the
z-axis. All settings were kept constant to allow comparison. For
double immunoﬂuorescence, dual excitation using the multitrack
mode (images taken sequentially) was achieved using the argon
and He/Ne lasers.2.8. Statistical analysis
All quantitative data are presented asmean of at least 3 independent
experiments ± SEM. One-way ANOVA tests were performed for com-
parisons between multiple groups. Statistical comparisons of 2 groups
were done by an unpaired Student's t-test. Differences were considered
signiﬁcant for P b 0.05.
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3.1. Identiﬁcation of SERCA isoforms expressed in normal mouse cardiovas-
cular tissues
The SERCA system of themouse heart was ﬁrst characterized in nor-
mal C57-BL/6 mice by RT-PCR and western blot (Fig. 1A & B). RT-PCR
analysis revealed the expression of at least 5 SERCA isoforms in the
left and right ventricles: 2a, 2b, 3a, 3b and 3c (Fig. 1A). No SERCA2c
mRNA was found in mice, while a corresponding sequence displaying
66.7% of similarity for a score 96, was identiﬁed in the mouse SERCA2
gene (Fig. 1D). Expression of these isoforms in the heart at the protein
level was also conﬁrmed by immunoblot analysis (Fig. 1B). Absolute
quantitative real-time PCR shows SERCA2a to be the major cardiac iso-
form (~99.9%) whereas the ubiquitous SERCA2b represents less than
0.1% of total SERCA mRNA (Table 2). SERCA3 transcript variants were
all expressed at very low levels compared to SERCA2a and SERCA2b.
As shown in immunoﬂuorescent images (Fig. 1C), i) SERCA2awas locat-
ed in the longitudinal reticulum of cardiomyocytes, in opposite phase to
the position of the I-band (F-actin) indicated by phalloidin staining;
ii) SERCA2b demonstrated sub-compartmental localization and a
uniform distribution similar to SERCA2a. In contrast, the third
cardiac isoform SERCA3b co-localized with the I-bands (Fig. 1C),
suggesting an expression preferentially in the junctional reticulum,
near Z-band and traversal tubules. No speciﬁc localization for
minor SERCA isoforms (SERCA3a and 3c) was clearly observed in
cardiomyocytes, suggesting that these isoforms are more speciﬁc
to vascular cells.
The same isoforms were identiﬁed by RT-PCR analysis in WT
mouse aorta, but their relative expressions were different compared
to the heart (Table 2). SERCA2a appeared, once again, as the major
isoform in the normal aorta, but its expression is much lower than
in the heart (~30 pg/μg of RNA in aorta vs ~920 pg/μg of RNA in
the heart). Although SERCA2b expression was 0.86 and 1.6 pg/1 μg
of total RNA in the heart and aorta respectively, the percentage of
SERCA2a still represented more than 90% of total SERCA, and that
of SERCA2b isoform ~5%. Expression of SERCA3b is higher in the
aorta than in heart, respectively 1.01 ± 0.21 pg/μg RNA and 0.19 ±
0.07 pg/μg RNA. The percentage of SERCA3b (3.3%) is similar to that of
SERCA2bwhile the last two other SERCA3 isoforms remained poorly ex-
press in the aorta.
3.2. Localization of SERCA isoforms expressed in normal murine cardiovas-
cular tissues.
Confocal immunoﬂuorescence conﬁrmed distinct distribution of
SERCA isoforms within cardiomyocytes and vascular cells (Fig. 2). As
expected, SERCA2a was abundantly expressed in cardiomyocytes; in
the coronary arteries, SERCA2a expression was barely detectable inTable 2
Absolute quantiﬁcation of different SERCA variants mRNA in normal and diseased cardiovascu
SERCA
(pg/1 μg RNA)
Control heart
(n = 22)
Failing heart
(n = 23)
(Multiple comparison
P b 0.05
SERCA2a 919.4 ± 143.5 436.01 ± 61.6 ***
SERCA2b 0.86 ± 0.17 0.64 ± 0.11 ns
SERCA3a 0.003 ± 0.001 0.002 ± 0.0002 ns
SERCA3b 0.193 ± 0.08 0.028 ± 0.003 *
SERCA3c 0.014 ± 0.005 0.003 ± 0.001 ns
SERCA (%) Control heart (n = 22) Failing heart (n =
SERCA2a 99.89 99.84
SERCA2b 0.093 0.146
SERCA3a b0.001 b0.001
SERCA3b 0.021 0.006
SERCA3c 0.001 b0.001vascular smooth muscle cells (VSMC) but substantial in endothelial
cells (EC). Interestingly, in aorta samples, expression of SERCA2a, de-
tected by immunoﬂuorescence, was found in both vascular smooth
muscle and endothelial cells (Fig. 3). The ubiquitous SERCA2b isoform
was expressed at similar levels in every cell type (cardiomyocytes,
VSMC and EC) (Figs. 2 & 3), whereas SERCA3a isoform seemed restrict-
ed to EC. Of note, low expression of SERCA3a was also detected in aortic
VSMC (Fig. 3). In contrast, the SERCA3b isoform was strongly
expressed in VSMC and hardly in EC (Figs. 2 & 3). Finally, SERCA3c
isoform expression was faint in every cardiovascular cell type.
Remarkably, in EC, ubiquitous isoform SERCA2b and SERCA3b were
located in the basal part of the cell, whereas SERCA2a and SERCA3a
were positioned in the luminal part (Fig. 2), supporting the function-
al association of SERCA2a and SERCA3a required for NO synthesis
[19,24].
3.3. Alteration of expression and/or subcellular localization of SERCA
isoforms in cardiomyocytes during heart failure
The heart failure model used was myocardial infarction (MI) in-
duced by ligation of the left coronary artery in 2 month old C57BL6
mice. Progressive remodeling was evidenced by left ventricular
(LV) dilation and deterioration of LV function at 1 and 6 months
after infarction (Fig. 4A & Table 3). Six months after MI induction,
heart weight and heart weight/body weight or heart weight/tibia
length ratios were increased (Table 4). Furthermore, histological
examination revealed an increase of the size of LV cardiomyocytes
in MI mice (Fig. 4B) and ﬁbrosis in the scarred area of the myocardial
infarction (Fig. 4C).
In order to quantify mRNA expression, we ﬁrst determined the rate
of ampliﬁcation for each cDNA (Supplementary data Fig. 1S). Next, we
assessed SERCA isoform expression in the mouse model of heart failure
using real-time RT-PCR analysis and confocal immunoﬂuorescence mi-
croscopy (Fig. 5 & Table 2). Since a high level of ﬁbrosis was observed
in MI hearts, leading to a higher proportion of non-cardiomyocyte
cells, we used the ubiquitous GAPDH gene and cardiomyocyte speciﬁc
cardiac calsequestrin gene (CSQ) as reference gene since they have
been shown to be stable in the course of hypertrophic remodeling
[25]. As expected, the relative expression of SERCA2a transcripts was
signiﬁcantly decreased in failing hearts regardless of the reference
gene used (Fig. 5A & B), whereas that of SERCA2b remained unchanged.
Concerning the other SERCA isoform transcript expressions, a similar
decrease of expression was observed for SERCA3b and 3c in failing
hearts, while no signiﬁcant differences were obtained for SERCA3a
(Fig. 5C & D). These results were further conﬁrmed for SERCA2 (a and
b) isoforms at the protein level by western blot (Fig. 5E–G).
Cellular localization of SERCA isoforms within failing cardiomyocytes
was assessed by confocal microscopy immunoﬂuorescence (Fig. 5H). In
sham cardiomyocytes, SERCA2a and SERCA2b demonstrated a similarlar tissues.
test) WT aorta
(n = 9)
ApoE (−/−)
aorta (n = 8)
(Multiple comparison test)
P b 0.05
27.90 ± 6.64 13.77 ± 0.81 *
1.59 ± 0.19 1.61 ± 0.20 ns
0.016 ± 0.003 00.070 ± 0.025 *
1.01 ± 0.21 1.42 ± 0.15 ns
0.11 ± 0.01 0.12 ± 0.01 ns
23) WT aorta (n = 9) ApoE (−/−) aorta (n = 8)
91.07 81.15
5.19 9.47
0.05 0.41
3.30 8.28
0.38 0.69
10 µm
10µm
SERCA2a 
SERCA2b 
SERCA3a 
SERCA3b 
SERCA3c 
anti-SERCA zoom 
6.5 µm47 µm
47 µm
47 µm
47 µm
47 µm
6.5 µm
12 µm
EC
VSMC CM
CM
VSMC 
EC
CM
VSMC 
EC
EC
VSMC 
CM
CM
VSMC 
EC
anti-SERCA 
Phalloïdine 
Dapi 
Fig. 2. Expression of SERCA isoforms in cardiovascular tissues and cells. A. Localization of SERCA isoforms in the left ventricle of normal mice by cell type. Confocal immunoﬂuorescence
microscopy with SERCA-speciﬁc antibodies (green) of left ventricle sections from normal mice. Red—F-actin, phalloidin. Nuclei were stained with Dapi (blue). Abbreviations:
CM—cardiomyocytes; VSMC—vascular smooth muscle cells; EC—endothelial cells.
2710 L. Lipskaia et al. / Biochimica et Biophysica Acta 1843 (2014) 2705–2718subcompartmental localization in the longitudinal reticulum, in opposite
phase with the position of the Z-line, delineated by desmin staining
(Fig. 5H). In marked contrast, both of these SERCA2 isoforms wereco-localized with the Z-line area in failing cardiomyocytes, suggesting
a re-localization of these two proteins from the longitudinal to the junc-
tional reticulum.
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isoforms in vessels during atherosclerosis
We used hypercholesterolemic apolipoprotein−/−mice (ApoE−/−)
as a model of vascular remodeling (Fig. 6). Lesion development inthe brachiocephalic artery of ApoE−/− mice was visualized by high-
resolution ultrasound biomicroscopy. Plaque size signiﬁcantly in-
creased beginning at 42 weeks of age and continued to increase
until the end of the study (Fig. 6A). Lesion surface area was greatest
at 200 μm from the appearance of the ﬁrst aortic valve cusp and
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Table 3
Assessment of cardiac function by transthoracic echography in sham operated and MI mice, 1 and 6 months after surgery.
1 month after surgery 6 months after surgery
Sham operated (n = 7)
Mean ± SD
MI (n = 16)
Mean ± SD
p (t-test) Sham operated (n = 7)
Mean ± SD
MI (n = 15)
Mean ± SD
p (t-test)
HR (b/min) 512.4 ± 9.7 483.0 ± 16.1 p = ns 531.2 ± 15.9 493.5 ± 15.9 p = ns
IVSDT (mm) 0.61 ± 0.01 0.51 ± 0.01 p b 0.01 0.67 ± 0.04 0.61 ± 0.02 p = ns
IVSST (mm) 1.04 ± 0.02 0.86 ± 0.04 p b 0.05 1.21 ± 0.004 0.92 ± 0.03 p b 0.01
PWDT (mm) 0.82 ± 0.03 0.61 ± 0.02 p b 0.01 0.90 ± 0.03 0.71 ± 0.03 p b 0.01
PWST (mm) 1.20 ± 0.05 0.95 ± 0.07 p b 0.01 1.35 ± 0.05 1.03 ± 0.05 p b 0.01
H/R (IVSDT + PWDT) / LVEDD 4.07 ± 0.14 2.65 ± 0.13 p b 0.01 4.10 ± 0.24 2.92 ± 0.18 p b 0.01
The following parameters were measured: IVSDT: interventricular septum diastolic thickness; IVSST: interventricular septum systolic thickness; LVEDD: left ventricle end diastolic
diameter; LVESD: left ventricle end systolic diameter; PWDT; posterior wall diastolic thickness; PWST: posterior wall systolic thickness; EDV: end diastolic volume; ESV: end systolic
volume; EF: ejection fraction; FR: fractional shortening; Ejct vol: ejection volume; HR: heart rate; h/r = (IVSDT + PWDT)/LVEDD.
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Table 4
Morphometric analysis of sham operated and MI mice, 6 months after surgery.
Sham operated (n = 7) Mean ± SD MI (n = 15) Mean ± SD p (t-test)
Body weight (g) 30.86 ± 0.34 30.67 ± 0.41 ns
Heart weight (mg) 155.30 ± 2.76 197.7 ± 11.21 p b 0.001
Tibia length (cm) 1.78 ± 0.02 1.79 ± 0.02 ns
Heart/body weight 5.04 ± 0.08 6.45 ± 0.37 p b 0.001
Heart/tibia length 87.01 ± 1.63 110.05 ± 5.977 p b 0.001
2713L. Lipskaia et al. / Biochimica et Biophysica Acta 1843 (2014) 2705–2718smallest at 800 μm, corresponding to the emergence of the aorta
(Fig. 6B).
Given that the development of atherosclerotic lesions is associat-
ed with the trans-differentiation of VSMC from a contractile towards
synthetic/proliferating/inﬂammatory phenotype [18,26], we ﬁrst
analyzed the expression of markers of phenotype and inﬂammation
(Fig. 7A). The expressions of smooth muscle myosin heavy chain
alpha (α-MHC), SM22 alpha (SM22) and smoothelin, all markers of
contractile smooth muscle, were signiﬁcantly decreased in thoracic
aortas from ApoE−/− mice with atherosclerotic plaques (Fig. 7A). In
contrast, the expression of E-selectin, a cell adhesion molecule
expressed only in endothelial cells activated by cytokines and known
toplay an important role in the recruitment of these cells to inﬂammatory
sites, was signiﬁcantly increased in atherosclerotic vessels (Fig. 7A),
conﬁrming the phenotypic transition of VSMCs in thoracic aorta from
ApoE−/−mice.
Pathological vascular remodeling in ApoE−/−mice was associated
with a 2 fold decrease of the major isoform SERCA2a (Fig. 7B &
Table 2). Furthermore, SERCA2b, SERCA3b and SERCA3c expressions
were also decreased in atherosclerotic vessels (Fig. 7B & C; Table 2). Re-
markably, the expression of SERCA3a isoform augmented 8 fold even if
its percentage only reached 0.4% in ApoE−/− mice aorta (Fig. 7C;
Table 2).
Histological analysis conﬁrmed the presence of atherosclerotic le-
sions on aortic roots of all ApoE−/− animals; no lesions were observed
in control mice (Fig. 6). The media area of aortic root atherosclerotic le-
sions, deﬁned by elastin layers (Fig. 7D), was severely damaged and
contained a large area composed of crowded elastic ﬁbers lacking
VSMC. Abundant neointima, deﬁned as a layer within the internal elas-
tic lamina (IEL) and lumen, was clearly identiﬁed in aortic roots from
ApoE−/− animals. SERCA2a was expressed in both VSMC and EC of aor-
tic roots (Fig. 7D), in agreement with our observations in coronary ves-
sels and in the aorta (Fig. 2 & 3). As expected, SERCA3a expression was
highest in the EC layer (Fig. 8D). SERCA2a expression was dramatically
decreased in both neointima and media of atherosclerotic lesions in
ApoE−/−mice. Nevertheless, SERCA2a was still detected in the luminal
part of atherosclerotic vessels suggesting its expression in ECs. Further-
more, SERCA3a was abundantly expressed in the luminal part of the
atherosclerotic vessels suggesting an enlargement of the endothelial
cell layer. Large and round SERCA3a positive cells were also visualized
in the neointima.
4. Discussion
We demonstrated the simultaneous expression of several SERCA
isoforms with differential calcium afﬁnity and pump activity in mouse
cardiomyocytes, VSMC and endothelial cells and their dynamic varia-
tion and reorganization in disease states.
4.1. In mouse cardiomyocytes
The SERCA system is composed of at least 4 isoforms: SERCA 2a, 2b,
3b and 3c each with a speciﬁc intracellular location, as illustrated in
Fig. 8A. In human heart, we previously described at least 6 SERCA
isoforms: SERCA2a, 2b, 2c and SERCA3a, 3d and 3f [1,22].We, and others [1,15], using relative mRNA quantiﬁcation, have
identiﬁed SERCA2a as the major cardiac isoform and SERCA2b as a
minor cardiac isoform. Here, we observed a global reduction of both
SERCA2 and SERCA3 expression in our pathological model. We also re-
port that even though SERCA2a is down-regulated during pathologic
cardiac hypertrophy and heart failure, its relative expression remains
largely predominant. Observation from previousworks from transgenic
mice clearly suggested that the level of SERCA2a expression is critical.
Wuytack et al. have produced transgenic mice in which SERCA2a was
replaced by SERCA2b, resulting in cardiac dysfunction and hypertrophy
[27], showing that the high Ca2+ afﬁnity SERCA2b isoforms appeared to
be an inadequate substitute for SERCA2a. The total level of SERCA2 was
lower in SERCA2a-deﬁcient mice in an initial study, but further
overexpression of SERCA2b in these cardiomyocytes led to increased
SR calcium transport and enhanced mechanical function (contractility
and relaxation), without preventing cardiac hypertrophy [15] or ﬁbrosis
[4]. Althought, a spontaneous two-fold increase in cardiac phospholam-
ban expression might counteract a possible effect of SERCA2b [27]. In-
terestingly, SERCA2b/WT heterozygous mice in which the natural
SERCA2a isoform is the major isoform do not present hypertrophy,
conﬁrming that SERCA2a is necessary and most likely sufﬁcient.
Reduced SERCA2a activity and SR Ca2+ uptake lead to abnormal Ca2+
handling in failing cardiomyocytes including an increase in diastolic
Ca2+, abnormally long time course of Ca2+ transients, and decrease in
SR Ca2+ release [28]. Furthermore, reduction of SERCA2a expression by
RNA silencing in cardiac myocytes resulted in increased expression of
transient receptor potential channels (TRPC) and activation of the
calcium/calcineurin-dependent complex [29]. These Ca2+-dependent
signaling pathways initiate and sustain hypertrophic growth and remod-
eling, which often progress to heart failure [20,28]. By lowering cytosolic
Ca2+, SERCA2a expression inhibits calcineurin activity and associated
hypertrophic and apoptotic signaling pathways [30].
Similarly to what was described in human cardiomyocytes, both
SERCA2a and SERCA2b proteins were targeted to the same subcellular
regions (longitudinal SR) [1,4,31]. In the normal condition, SERCA2
proteins were found in opposite phase to the position of the I-band, in
the SR wrapping myoﬁlaments. This is consistent with the SR being
the source of large Ca2+ mobilization into the cytosol, during cardiac
excitation–contraction coupling, essential to produce a rapid increase
in cytosolic [Ca2+] responsible for activation of the myoﬁlaments to be
translated into a proper twitch contraction. The rate of the rise of cyto-
solic Ca2+ depends on the triggering and gating of the RyR and the
amount of Ca2+ available in SR for release [32].
We have found that in cardiomyocytes from failing hearts, SERCA2
proteins relocated to the Z-line (Fig. 8B). The Z line is closer to extracel-
lular exchange area (T-tubule) and contains LTCC and RyR channels. The
LTCCs and RyR form couplons at the interface between the sarcolemma
and the junctional SR. A defective coupling of Ca2+ inﬂux via LTCC,
preventing the activation of RyR, has been implicated in a reduced SR
Ca2+ release in heart failure. Both functional changes in LTCC properties
and structural re-organization of this L-type channel within T-tubules
could be involved [33]. Relocation of SERCA2 to the Z-line in
hypertrophiedmyocytesmight be associated to T-tubule disorganization
shown to coincide with myocardial dysfunction and calcium transient
abnormalities in hypertensive rats [34] and suggest a compensation of
defective LTCC/RyR coupling by rising available SR Ca2+ content.
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
m
R
N
A 
ex
pr
es
si
on
 
m
RN
A
 e
xp
re
ss
io
n 
A B 
Sh MI Sh MI Sh MI Sh MI 
SERCA2a SERCA2b SERCA2b SERCA2a 
C 
m
 R
N
A 
ex
pr
es
si
on
 
SERCA3a SERCA3b SERCA3c
Sh MI Sh MI Sh MI
* *
m
 R
N
A 
ex
pr
es
si
on
 
SERCA3a SERCA3b SERCA3c
Sh MI Sh MI Sh MI
* *
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
D 
H 
E
SERCA2a 
Sh MI
SERCA2b 
CSQ 
GAPDH Sh  MI 
SERCA2a 
Sh  MI
SERCA2b 
Sh  MI 
SERCA2a 
Sh  MI 
SERCA2b 
F G 
MI LVSham LV MI LVSham LV
R
el
at
iv
e 
no
rm
al
iz
ed
R
el
at
iv
e 
no
rm
al
iz
ed
R
el
at
iv
e 
no
rm
al
iz
ed
R
el
at
iv
e 
no
rm
al
iz
ed
Fig. 5. Alteration of SERCA isoform expression in the failing heart. Relative expression of SERCA 2a and 2b variants in sham- (n= 9) and MI- (n= 20) operated animals normalized on
calsequestrin (CSQ) (A) and GAPDH (B). Relative expression of SERCA 3a, 3b and 3c variants in sham- (n= 12) and MI- (n= 20) operated animals normalized on calsequestrin (CSQ)
(C) and GAPDH (D). E. Immunoblot analysis (left panel) and bar-graph representing normalized relative quantiﬁcation of SERCA2a and SERCA2b expression in sham-operated and MI
animals. F. Localization of SERCA2a and SERCA2b within cardiomyocytes from sham (left panel) and MI (right panel) mouse hearts. Upper panel: Confocal microscopy immunoﬂuores-
cence with a-SERCA (red) and a-desmin (green) antibodies on transverse sections. Lower panel: Analysis of SERCA and desmin colocalization in normal and failing cardiomyocytes.
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Fig. 6. Atherosclerotic plaques in aged ApoE (−/−) mice. A. Lesion development in the
brachiocephalic artery of ApoE KO mice visualized by high-resolution ultrasound
biomicroscopy (UBM). Lesion size (y axis, mm2) was measured for every mouse at all
time points examined. The study began at 33 weeks of age and images were taken
every 3 weeks until the end of the study at 48 weeks of age. The ultrasound images
underneath the graph represent plaque development at 33, 39 and 48 weeks of age. The
atherosclerotic plaques are contoured in white lines. Plaque surface area was calculated
by the VEVO software. B. Quantiﬁcation of atherosclerotic lesion surface area in the aortic
roots of ApoE KO mice. Lipid content was quantiﬁed on aortic root cryosections from
48 week old mice stained with oil red O and analyzed under polarized light. The distance
from the valve origin represents 200, 400, 600, and 800 μmfrom theappearance of theﬁrst
aortic valve cusp; 800 μm is the emergence of the aorta (800 μm). n= 6.
2715L. Lipskaia et al. / Biochimica et Biophysica Acta 1843 (2014) 2705–2718Remarkably, relocation of SERCA2 from the SR wrapping myoﬁlaments
might result in slow rise Ca2+ inﬂux across the sarcolemma ensuing in
inefﬁcient contraction.
Themouse SERCA system expressed in the heart is also distinct from
the human one, as no SERCA2cmRNAwas found inmice.While the role
played by SERCA2C in human heart remained to be clariﬁed, its speciﬁc
localization to longitudinal SR and intercalated discs in close proximity
to the sarcolemma, an area that could display relatively high calcium
concentration, was in agreement with its lower apparent afﬁnity for
Ca2+. Such localization was not observed for SERCA expressed in
mouse cardiomyocyte. But it is possible that some function associated
to SERCA2c in human heart could be done by SERCA3b which also
share similar afﬁnity for Ca2+.
Among SERCA3 isoforms, only SERCA3b was clearly identiﬁed in
mouse cardiomyocytes by its speciﬁc location at the junctional SR,
near the T-tubules, which corresponds to the localization of SERCA3a
in human cardiomyocytes [1]. It is tempting to imagine that this area
is more adapted to the SERCA3 protein as it can be richer in Ca2+ (due
to its interaction with the extracellular medium), considering that
SERCA3 works at a higher Ca2+ concentration than SERCA2 isoforms.Limited data are available on human failing cardiac tissue, in which
only a signiﬁcant increase in SERCA3fwas recently demonstrated, in ad-
dition to the well-established decrease in SERCA2a [1]. While the SR
regulates excitation–contraction coupling due to its special ability to
store calcium, the role of the ER in protein synthesis and processing
and the disruption of such processes in pathologic situations (known
as ER stress) is of growing importance in cardiomyocyte and in heart
failure [1]. In this regard, an interesting connection can be made be-
tween 1) the increased expression of SERCA3f in human heart failure
with a parallel increase in ER stress markers [22], and 2) the ability of
SERCA3f to induce ER stress and apoptosis in HEK-293 cells [35].
SERCA3f and SERCA3b share the same C-terminal end and SERCA3b
was also able to induce ER stress in human cells. However, it is not
clear whether SERCA3b can be seen as an equivalent of SERCA3f in
mice, as it is down-regulated in heart failure while SERCA3f expression
was described to increase.
4.2. In vascular smooth muscle cells
The SERCA system is composed of at least 4 isoforms: SERCA 2a, 2b,
3b and 3c. As opposed to previous studies [16], SERCA2a was identiﬁed
as a major isoform in both contractile and synthetic VSMC using the
method of absolute mRNA quantiﬁcation. Technical differences may
account for the different results. This ﬁnding is novel but not surprising
taking into account that synthetic VSMCs are able to produce tonic
contraction (rev. [18,19]). In VSMCs, oscillatory type of Ca2+ transients
triggers phasic contraction, typical of coronary and low resistance
arteries highly expressing SERCA2a. Tonic contractions observed in
large arteries and veins are driven by the steady-state increase in
cytosolic Ca2+, observed also in synthetic VSMC (rev. [18,19]). Sev-
eral observations support the evidence that the calcium response
shape appears to be dependent on SERCA2a expression: 1) blocking
SERCA activity also strongly inhibits the Ca2+ oscillations, demon-
strating that they are caused by release of Ca2+ from the SR
[36–38]; 2) trans-differentiation of VSMC towards synthetic phe-
notype is associated with a loss of both Ca2+ oscillations and
SERCA2a expression (this paper and [39,40]; and 3) SERCA2a
gene transfer to synthetic cultured VSMC modiﬁes the agonist-
induced calcium transient from steady-state to oscillatory mode
[41]. Importantly, restoring SERCA2a expression by gene transfer
in synthetic cultured VSMC also inhibits Ca2+ dependent activation
of transcription factor NFAT required for proliferation and migration of
VSMC [30,41,42].
We also report a relatively high expression of the SERCA3b
isoform in mouse VSMC, similar to one of the ubiquitous SERCA2b
isoform. In humans, SERCA3b have been found highly expressed in
the lung, kidney and pancreas; however its cellular localization and
speciﬁc function have not yet been investigated [19]. The fact that
SERCA3b expression appears to be important in normal VSMC and
its speciﬁc localization in cardiomyocytes at the junctional SR near
T tubules suggests that it could be involved in interaction with
extracellular Ca2+ inﬂux.
4.3. In endothelial cells
The SERCA system is composed of at least 5 isoforms: SERCA2a, 2b,
3a as well as the slightly expressed 3b and 3c. First, we have detected
a strong expression of SERCA3a in EC, conﬁrming previous observations
describing SERCA3a as a major endothelial-speciﬁc isoform [43]. Sec-
ond, according to immunolabeling data, SERCA2a appears to be a
major isoform co-expressed with SERCA3a in the luminal part of EC.
This latter observation is consistent with the described role of SERCA3a
and SERCA2a in EC related to the regulation of NO synthesis from
L-arginine by the nitric oxide synthase (eNOS, endothelial nitric
oxide synthase) (rev in [19,44]). Several observations support the coop-
erative action of SERCA2a and SERCA3a in the control of NO production
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2716 L. Lipskaia et al. / Biochimica et Biophysica Acta 1843 (2014) 2705–2718in EC: 1) ablation of SERCA3 genes results in defective nitric oxide (NO)
synthesis [45]; 2) SERCA2a and SERCA3a colocalize with eNOS and cav-
eolin in sub-plasma membrane reticulum in EC [19,24]; and 3)overexpression of SERCA2a in human EC, resulting in increased ER
Ca2+ storage and mobilization, also enhances eNOS activity and cGMP
production [24].
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Fig. 8. Schematic localization of SERCA isoforms in normal and hypertrophied cardiomyocytes. Schematic representations of the structure of normal (Panel A) and failing (Panel B) cardiac
myocytes illustrate the relative position of the SERCA isoforms on the SR network that wrap around the myoﬁbrils. Panel C shows the topology of a myoﬁbril.
2717L. Lipskaia et al. / Biochimica et Biophysica Acta 1843 (2014) 2705–2718We report an increase in SERCA3a expression in atherosclerotic ves-
sels, together with a modiﬁcation of the pattern of expression. The in-
crease in SERCA3a expression might compensate the decrease of
SERCA2a. However, the SERCA3a expression appears more diffuse at
the atherosclerosis site compared to its normal localization. Given the
fact that SERCA3a is preferentially expressed by endothelial cells and
blood cells [46,47], it is interesting to suggest that SERCA3a expression
indicates the inﬁltration of endothelial cells precursors or monocytes
in the neointima of atherosclerotic vessels, as it is described (intimal hy-
perplasia in murine models [48].5. Conclusions
The simultaneous expression of several SERCA isoforms in cardio-
vascular cells enlightens possible functions for each of the SERCA iso-
forms, given the speciﬁc expression and localization. Data obtained in
a particular set of pathological conditions revealed speciﬁc regulation
of SERCA isoforms, suggesting that not only the variety, but also the
combination of SERCA isoforms achieves tight regulation of cellular
functions.We have identiﬁed SERCA2a as themajor isoform in both car-
diac and vascular myocytes, in normal and pathological conditions. The
expression of SERCA2a mRNA is ~30 fold higher in the heart compared
to vascular tissues, in conformity with highest impact of contractile
function in cardiomyocyte physiology. Notably, nearly half the amount
of SERCA2amRNA is measured in both failing cardiomyocytes and syn-
thetic VSMCs compared to healthy tissues. Our study shows that the
SERCA2a isoform is the principal regulator of excitation–contraction
coupling in both CMs and contractile VSMCs and supports a dynamic
and integrated regulation of the SERCA isoform system. The roles of
previously unexplored isoforms, along with the dynamic interactions
between isoforms, deserve further studies.
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